SERUM BETA-ENDORPHIN LEVEL IN PATIENTS WITH METABOLIC SYNDROME AND SEBORRHEIC DERMATITIS
DOI:
https://doi.org/10.11603/1811-2471.2022.v.i4.13500Keywords:
beta-endorphin, non-alcoholic fatty liver disease, chronic pancreatitis, type 2 diabetes, seborrheic dermatitisAbstract
SUMMARY. Endogenous opioids synthesized by adenohypophysis modulate the release of pancreatic hormones and expression of μ- and δ-opioid receptors. Beta-endorphin is present in pancreatic islets, suggesting that endogenous opioids may be secreted locally to regulate pancreatic function. There is a limited number of studies describing changes in levels of glucose and insulin after beta-endorphin exposure. Opioids have a hypoglycemic effect in patients with a baseline increase of glucose level. There is a dose depending effect of opioids on blood sugar in obese patients. At very low concentrations β-endorphin raises blood glucose levels in obese subjects without affecting blood glucose levels in healthy weight subjects.
The aim – to determine the level of beta-endorphin in patients with metabolic syndrome with/without seborrheic dermatitis.
Material and Methods. Patients with non-alcoholic fatty liver disease (NAFLD) in combination with chronic pancreatitis (CP) against the background of body mass index (BMI) disorders (overweight or obesity of various degrees) and type 2 diabetes were examined. The 1st group included patients without any skin diseases, the 2nd with seborrheic dermatitis. Controls were healthy individuals of the same age. Determination of the level of beta endorphin was carried out by the ELISA method with the test system Human Beta-endorphin NBP2 – 78774 Novus Biologicals. Statistical analysis by STATISTICA 10.0 program.
Results. The level of beta-endorphin in the group of patients with metabolic syndrome combined with seborrheic dermatitis was significantly higher, compared to the control group (respectively, 38±2.1 pg/mL; 22±4.1 pg/mL; p<0.000001) and significantly lower in individuals with metabolic syndrome without signs of skin inflammation 19±2.6 pg/mL. The obtained results are similar to those described in various studies, but do not explain the mechanisms of sugar level regulation by beta endorphin, but only state the fact of the presence of insulin/glucagon-mediated and independent regulation mechanisms.
Conclusions. patients with diabetes, hyperglycemia, insulin resistance in combination with obesity and dyslipidemia have lower level of beta endorphin than in healthy individuals. Presumably, seborrheic dermatitis increases the release of beta endorphin due to the presence of constant inflammation and itching of the skin, which contributes to its increase compared to healthy people.
References
Benarroch, E.E. (2012). Endogenous opioid systems: current concepts and clinical correlations. Neurology, 79(8), 807-814.
Shenoy, S.S., & Lui, F. (2022). Biochemistry, Endogenous Opioids. Jun 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. PMID: 30422494.
Tudurí, E., Beiroa, D., Stegbauer, J., Fernø, J., López, M., Diéguez, C., & Nogueiras, R. (2016). Acute stimulation of brain mu opioid receptors inhibits glucose-stimulated insulin secretion via sympathetic innervation. Neuropharmacology, 110(A), 322-332.
Reid, R.L., & Yen, S.S. (1981). Beta-Endorphin stimulates the secretion of insulin and glucagon in humans. J. Clin. Endocrinol. Metab,, 52(3), 592-594.
Inder, W.J., Livesey, J.H., Ellis, M.J., Evans, M.J., & Donald, R.A. (1996). The effect of beta-endorphin on basal and insulin-hypoglycaemia stimulated levels of hypothalamic-pituitary-adrenal axis hormones in normal human subjects. Clin. Endocrinol. (Oxf.), 44(1), 7-13.
Brase, D.A., Singha, A.K., Estrada, U., Lux, F., & Dewey, W.L. (1990). Hypoglycemia induced by intrathecal opioids in mice: stereospecificity, drug specificity and effect of fasting. J. Pharmacol. Exp. Ther., 253(3), 899-904.
Khawaja, X.Z., & Green, I.C. (1991). Dual action of beta-endorphin on insulin release in genetically obese and lean mice. Peptides, 12(2), 227-233.
Radosevich, P.M., Lacy, D.B., Brown, L.L., Williams, P.E., & Abumrad, N.N. (1989). Central effects of beta-endorphins on glucose homeostasis in the conscious dog. Am. J. Physiol., 256(2, 1), e322-330.
Giugliano, D., Cozzolino, D., Salvatore, T., Ceriello, A., Torella, R., Franchimont, P., Lefebvre, P.J., & D'Onofrio, F. (1992). Physiological elevations of plasma beta-endorphin alter glucose metabolism in obese, but not normal-weight, subjects. Metabolism, 41(2), 184-190.
Giugliano, D., Salvatore, T., Cozzolino, D., Ceriello, A., Torella, R., & D'Onofrio, F. (1987). Hyperglycemia and obesity as determinants of glucose, insulin, and glucagon responses to beta-endorphin in human diabetes mellitus. J. Clin. Endocrinol. Metab., 64(6), 1122-1128.
Giugliano, D., Cozzolino, D., Salvatore, T., Torella, R., & D'Onofrio, F. (1988). Beta-endorphin-induced inhibition and stimulation of insulin secretion in normal humans is glucose dependent. Diabetes, 37(9), 1265-1270.
Kjaer, A., Knigge, U., Madsen, E.L., Søe-Jensen, P., Bach, F.W., & Warberg, J. (1993). Insulin/hypoglycemia-induced adrenocorticotropin and beta-endorphin release: involvement of hypothalamic histaminergic neurons. Endocrinology, 132(5), 2213-2220.
Pierce, E.F., Eastman, N.W., Tripathi, H.L., Olson, K.G., & Dewey, W.L. (1993). Beta-endorphin response to endurance exercise: relationship to exercise dependence. Percept. Mot. Skills, 77(3, 1), 767-770.
Goldfarb, A.H., & Jamurtas, A.Z. (1997). Beta-endorphin response to exercise. An update. Sports Med., 24(1), 8-16.
Balon-Perin, S., Kolanowski, J., Berbinschi, A., Franchimont, P., & Ketelslegers, J.M. (1991). The effects of glucose ingestion and fasting on plasma immunoreactive beta-endorphin, adrenocorticotropic hormone and cortisol in obese subjects. J. Endocrinol. Invest., 14(11), 919-925.
Scavo, D., Facchinetti, F., Barletta, C., Petraglia, F., Buzzetti, R., Monaco, M., Giovannini, C., & Genazzani, R. (1987). Plasma beta-endorphin in response to oral glucose tolerance test in obese patients. Horm. Metab. Res., 19(5), 204-207.
Wanke, T., Auinger, M., Formanek, D., Merkle, M., Lahrmann, H., Ogris, E., Zwick, H., & Irsigler, K. (1996). Defective endogenous opioid response to exercise in type I diabetic patients. Metabolism, 45(2), 137-142.
Peng, J., Sarkar, S., & Chang, S.L. (2012). Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. Drug Alcohol. Depend., 124(3), 223-228.
Zhang, M., Zheng, M., & Schleicher, R.L. (1992). Localization of beta-endorphin in rabbit pancreatic islets. Mol. Cell Neurosci., 3(6), 536-547.
Paul, A., Guven, N., & Dietis, N. (2014). Opioid receptor-dependent modulation of insulin-release in pancreatic beta-cells. UK J. Pharm. Biosci., 2(6), 22-31.
García-Barrado, M.J., Iglesias-Osma, M.C., Rodríguez, R., Martín, M., & Moratinos, J. (2002). Role of mu-opioid receptors in insulin release in the presence of inhibitory and excitatory secretagogues. Eur. J. Pharmacol., 448(1), 95-104.
Green, I.C., Perrin, D., Pedley, K.C., Leslie, R.D., & Pyke, D.A. (1980). Effect of enkephalins and morphine on insulin secretion from isolated rat islets. Diabetologia, 19(2), 158-161.
Reid, R.L., Sandler, J.A., & Yen, S.S. (1984). Beta-endorphin stimulates the secretion of insulin and glucagon in diabetes mellitus. Metabolism, 33(3), 197-199.
Schleicher, R.L. (1989). Beta-endorphin inhibits insulin secretion from isolated pancreatic islets. Endocrinology, 124(3), 1254-1258.
Su, C.F., Chang, Y.Y., Pai, H.H., Liu, I.M., Lo, C.Y., & Cheng, J.T. (2004). Infusion of beta-endorphin improves insulin resistance in fructose-fed rats. Horm. Metab. Res., 36(8), 571-577.
Mendez, I.A., Ostlund, S.B., Maidment, N.T., & Murphy, N.P. (2015). Involvement of Endogenous Enkephalins and β-Endorphin in Feeding and Diet-Induced Obesity. Neuropsychopharmacology, 40(9), 2103-2112.
Mousa, R.F., Smesam, H.N., Qazmooz, H.A., Al-Hakeim, H.K., & Maes, M. (2021). A pathway phenotype linking metabolic, immune, oxidative, and opioid pathways with comorbid depression, atherosclerosis, and unstable angina. CNS Spectr., 27, 1-15.
Okano, T., Sato, K., Shirai, R., Seki, T., Shibata, K., Yamashita, T., Koide, A., Tezuka, H., Mori,Y., Hirano ,T., & Watanabe, T. (2020). β-Endorphin Mediates the Development and Instability of Atherosclerotic Plaques. Int. J. Endocrinol., 28, 4139093.
Qazmooz, H.A., Smesam, H.N., Mousa, R.F., Al-Hakeim, H.K., & Maes, M. (2021). Trace element, immune and opioid biomarkers of unstable angina, increased atherogenicity and insulin resistance: Results of machine learning. J. Trace Elem. Med. Biol., 64, 126703.
Akintoye, O.O., Owoyele, B.V., Fabunmi, O.A,, Raimi, T.H., Oniyide, A.A., Akintoye, A.O., Ajibare, A.J., Ajayi, D.D., & Adeleye, G.S. (2020). Diabetic neuropathy is associated with increased pain perception, low serum beta-endorphin and increase insulin resistance among Nigerian cohorts in Ekiti State. Heliyon, 6(7), e04377.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Achievements of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
